SCHEMBL6414224

SCHEMBL6414224

CN1C(=O)c2ccccc2C(C(=O)N2CCOCC2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
TSHR P16473 7/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
MAPK1 P28482 1/20 0.49
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.44
FFAR1 O14842 1/20 0.43
TACR1 P25103 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418774 0.90 TSHR (0.54) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6410875 0.89 TSHR (0.53) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6416819 0.83 CYP3A4 (0.65) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6410237 0.83 FFAR1 (0.61) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6410233 0.83 FFAR1 (0.61) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6411903 0.82 HTT (0.48) ALDH1A1TSHRSMN1; SMN2CYP3A4CYP2C9
SCHEMBL6419719 0.81 HSD17B10 (0.50) ALDH1A1TSHRSMN1; SMN2CYP3A4KMT2A
SCHEMBL6413424 0.79 MAPT (0.46) ALDH1A1TSHRSMN1; SMN2CYP3A4KMT2A
SCHEMBL6413120 0.78 FFAR1 (0.41) ALDH1A1TSHRSMN1; SMN2CYP3A4KMT2A
SCHEMBL6413323 0.78 HSD17B10 (0.52) ALDH1A1TSHRSMN1; SMN2CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD ALDH1A1 1368/4885TSHR 4878/4885SMN1; SMN2 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.